medigraphic.com
Boletín Médico del Hospital Infantil de México

2009, Número 3

<< Anterior Siguiente >>

Bol Med Hosp Infant Mex 2009; 66 (3)


Tratamiento antimicótico empírico de pacientes inmunocomprometidos con neutropenia y fiebre persistente con sospecha de aspergilosis sistémica: análisis de costo-efectividad en México..

Mould-Quevedo JF, Contreras-Hernández I, Gómez-Morales E, Mejía-Arangure JM, Garduño-Espinosa J

Idioma: Español
Referencias bibliográficas: 67
Paginas: 241-253
Archivo PDF: 167.76 Kb.


RESUMEN

Introducción. Las micosis sistémicas generan un gran incremento en los costos de la atención médica. Se evaluó el medicamento más costo-efectivo para el tratamiento empírico de aspergilosis sistémica entre la anfotericina B, caspofungina y voriconazol en pacientes con fiebre persistente y neutropenia. Métodos. Modelo tipo árbol de decisiones para estimar los resultados clínicos esperados y los costos asociados del tratamiento de la aspergilosis sistémica. La perspectiva del estudio fue la del proveedor de servicios públicos de salud (Instituto Mexicano del Seguro Social [IMSS]). Temporalidad: 12 semanas. Medida de efectividad: tasa de remisión completa de la infección micótica. Se desarrollaron análisis de sensibilidad univaridos y probabilísticos. Resultados. Los costos totales promedio por paciente esperados para el tratamiento empírico de aspergilosis resultaron con voriconazol en $57 378.58 US; $72 833.96 US con anfotericina B, y de $49 962.37 US con caspofungina. La tasa de remisión total sin eventos adversos fue de 37% para caspofungina, 43.6% para voriconazol y de 51.1% para anfotericina B. El análisis de sensibilidad probabilístico muestra que voriconazol sería el tratamiento más costo-efectivo en 65% de los casos, independientemente de la disposición a pagar por el IMSS. Conclusiones. Los resultados presentados concuerdan con la afirmación de que el tratamiento estándar de primera línea recientemente propuesto para el tratamiento empírico de aspergilosis sistémica debe ser voriconazol.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Burgos A, Zaoutis TS, Dvorak CC, Hoffman JÁ, Knapp KM, Nania JJ, et al. Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008; 121: e1286-e94.

  2. Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB. Invasive fungal infections in pediatric oncology patients; 11 years experience at a single Institution. J Pediatr Hematol Oncol. 2005; 27: 135-40.

  3. Trigg ME, Morgan D, Burns TL, Kook H, Rumelhart SL, Holida MD, et al. Successful program to prevent Aspergillus infections in children undergoing marrow transplantation: Use of nasal amphotericin. Bone Marrow Transplant. 1997; 19: 43-7.

  4. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998; 26: 781-805.

  5. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica. 2006; 91: 1068-75.

  6. Chang DC, Burwell LA, Lyon M, Pappas PG, Chiller TM, Wannemuehler KA, et al. Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis. Infect Control Hosp Epidemiol. 2008; 29: 25-30.

  7. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogenic hematopoietic item cell transplant recipients. Mycopathologia. 2006; 162: 1-15.

  8. Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KVI. Infections in the neutropenic patient new views of an old problem. Hematology. 2001: 113-30.

  9. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46: 327-60.

  10. Méan M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Critical Care. 2008; 12: 204.

  11. Stevens DA. Diagnosis of fungal infections: Current status. J Antimicrob Chemother. 2002: 49 Supl 1: 11-9.

  12. Chandrasekar PH, Cutright JL, Manavathu EK. Aspergillus: Rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999. Diagn Microbiol Infect Dis. 2001; 41: 211-4.

  13. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996; 23: 608-15.

  14. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: Pharmacokinetics, safety and efficacy. Drugs. 2004; 64: 1997-2020.

  15. Ullman AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin. 2003; 19: 263-71.

  16. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet. 2005; 366: 1013-25.

  17. Roilides E. Early diagnosis of invasive aspergillosis in infants and children. Med Mycol. 2006; 44: S199-S205.

  18. Maschmeyer G, Haas A, Cornely A. Invasive aspergillosis. Epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007; 67: 1567-601.

  19. Rotstein C, Laverdière M, Marciniak A, Ali F. An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada. Can J Infect Dis Med Microbiol. 2004; 15: 277-84.

  20. Krishnan-Natesan S, Chandrasekar PH. Current and future therapeutic options in the management of invasive aspergillosis. Drugs. 2008; 68: 265-82.

  21. Blyth CC, Palasanthiran P, O’Brien TA. Antifungal therapy in children with invasive fungal infections: A systematic review. Pediatrics. 2007; 119: 772-84.

  22. Scott LJ, Simpson D. Voriconazole. A review of its use in the management of invasive fungal infections. Drugs. 2007; 67: 269-98.

  23. Van Gool R. The cost of treating systemic fungal infections. Drugs. 2001; 61 Supl1: 49-56.

  24. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006; 117: e711-6.

  25. Soto J, Grau S, Mateu-de Antonio J. Eficiencia de voriconazol (V-Fend) en el tratamiento de la aspergilosis invasiva. Rev Esp Econ Salud. 2003; 2: 358-62.

  26. Wenzel R, del Favero A, Kibbler C, Rogers T, Rotstein C, Mauskopf J, et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother. 2005; 55: 352-61.

  27. Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ, et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis en Germany. Value Health. 2006; 9: 12-23.

  28. Collins CD, Stuntebeck ER, de Pestel DD, Stevenson JG. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Clin Drug Investig. 2007; 27: 233-41.

  29. Domínguez-Gil A, Martín I, García-Vargas M, del Castillo A, Díaz S, Sánchez C. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Clin Drug Investig. 2007; 27: 197-205.

  30. Muñoz-Hernández O, Garduño-Espinosa J, Pérez-Cuevas R. Higia y Panacea en la Salud y la Sociedad. Los sistemas de salud, un producto de la evolución social. Rev Med Inst Mex Seguro Soc. 2005; 43: 411-7.

  31. Instituto Mexicano del Seguro Social. Secretaría General. Aviso: Costos unitarios de la atención médica. Diario Oficial de la Federación. Martes 9 de marzo de 2004 - Primera Sección. p. 106-7.

  32. Web Instituto Mexicano del Seguro Social: www. imss.gob.mx. Acceso en marzo 2006.

  33. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002; 346: 225-34.

  34. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347: 2020-9.

  35. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden JR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004; 351: 1391-402.

  36. Massion PB, Dive AM, Doyen Ch, Bulpa P, Jamart J, Bosly A, et al. Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med. 2002; 30: 2260-70.

  37. Pettilä V, Pettilä M, Sarna S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in the prediction of hospital mortality in the critically ill. Crit Care Med. 2002; 30: 1705-11.

  38. Evison JM, Rickenbacher P, Ritz R, Gratwolch A, Haberthür Ch, Elsasser S, et al. Intensive care unit admission in patients with haematological disease: Incidence, outcome and prognostic factors. Swiss Med Wkly. 2001; 131: 681-6.

  39. Subirá M, Martino R, Gómez L, Martí JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies- a randomized, controlled trial. Eur J Haematol. 2004; 72: 342-7.

  40. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med. 1998: 105: 478-83.

  41. Herbecht R, Denning DW, Patterson TF, Bennett JE, Greene RD, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Egl J Med. 2002; 347: 408-15.

  42. Garber G. An overview of fungal infections. Drugs. 2001; 61 Supl 1: 1-12.

  43. Uzun O, Anaissie EJ. Outpatient therapy for febrile neutropenia: Who, when, and how? J Antimicrob Chemother. 1999; 43: 317-20.

  44. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J. 2005; 24: 167-74.

  45. Castagnola E, Cesaro S, Giacchino M, Livadiotti S, Tucci F, Zanazzo G, et al. Fungal infections in children with cancer. A prospective, multicenter surveillance study. Pediatr Infect Dis J. 2006; 25: 634-9.

  46. Lin SJ, Scranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis. 2001; 32: 358-66.

  47. Chen SCA, Sorrell TC. Antifungal agents. Med J Aust. 2007; 187: 404-9.

  48. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health. 2002; 5: 26-34.

  49. Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteinder D, Hiemenz S, Greenberg RN, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol. 2000; 18: 2476-86.

  50. Marbaix S, Marciniak A, de Mees V, Aoun M. Cost-effectiveness of voriconazole compared with conventional amphoteticin B in first line treatment of invasive aspergillosis in Belgium. J Antimicrob Chemother. 2005; 55: 352-61.

  51. Grau S, Meteu-de Antonio J, Soto J, Muñoz M, Salas E. Cost-effectiviness analysis of voriconazole versus amphotericin B in the treatment of invasive aspergillosis in Spain. Reporte Interno España. 2006.

  52. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003; 41: 3623-6.

  53. Goffeau A. The fight against fungi. Nature. 2008; 452: 541-2.

  54. Thakur JK, Arthanari H, Yang F, Pan SJ, Fan X, Breger J, et al. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature. 2008; 452: 604-9.

  55. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002; 34: 563-71.

  56. O’Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. Antifungal interaction within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother. 2006; 58: 1168-76.

  57. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling. Transformation, translation and appropriate application. Pharmacoeconomic. 2007; 25: 3-6.

  58. Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis. 2003; 3: 230-6.

  59. Groll AH, Attarbaschi A, Schuster FR, Herzog N, Grigull L, Dworzak MN, et al. Treatment with caspofungin in immunocompromised paediatric patients: A multicentre survey. J Antimicrob Chemother. 2006; 57: 527-35.

  60. Keating GM, Figgit DP. Caspofungin: A review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs. 2003; 63: 2235-63.

  61. McCormack PL, Perry CM. Caspofungin: A review of its use in the treatment of fungal infections. Drugs. 2005; 65: 2049-68.

  62. Kauffman CA. Fungal infections. Proc Am Thorac Soc. 2006; 3: 35-40.

  63. Karen B, Glenn C, Blomquist MJ, Horn N, Freeman P. Eliciting willingness to pay without bias: Evidence from a field experiment. Econ J. 2008; 118: 114-37.

  64. Horowitz JK, McConell KE. Willingness to accept, willingness to pay and the income effect. J Econ Behav Org. 2003; 51: 537-45.

  65. Jørgensen KJ, Gøtzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD004707. DOI: 10.1002/14651858.CD004707.pub2.

  66. Walsh TJ, Roilides E, Groll AH, González C, Pizzo PA. Infectious complications in pediatric cancer patients. En: Pizzo PA, Poplack DG, editores. Principles and practices of pediatric oncology. 5a ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2006. p. 1269-329.

  67. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics. Med Decis Making. 1994; 14: 259-65.




2020     |     www.medigraphic.com